- Home
- CVKD vs PWM Comparison
CVKD vs PWM Comparison
Compare CVKD & PWM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- PWM
- Stock Information
- Founded
- CVKD 2022
- PWM 2018
- Country
- CVKD United States
- PWM Hong Kong
- Employees
- CVKD N/A
- PWM N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- PWM
- Sector
- CVKD Health Care
- PWM
- Exchange
- CVKD Nasdaq
- PWM Nasdaq
- Market Cap
- CVKD 20.8M
- PWM 17.6M
- IPO Year
- CVKD 2023
- PWM 2023
- Fundamental
- Price
- CVKD $16.17
- PWM $1.16
- Analyst Decision
- CVKD Strong Buy
- PWM
- Analyst Count
- CVKD 2
- PWM 0
- Target Price
- CVKD $46.00
- PWM N/A
- AVG Volume (30 Days)
- CVKD 79.1K
- PWM 355.9K
- Earning Date
- CVKD 11-07-2024
- PWM 12-31-2024
- Dividend Yield
- CVKD N/A
- PWM N/A
- EPS Growth
- CVKD N/A
- PWM N/A
- EPS
- CVKD N/A
- PWM N/A
- Revenue
- CVKD N/A
- PWM $348,528.00
- Revenue This Year
- CVKD N/A
- PWM N/A
- Revenue Next Year
- CVKD N/A
- PWM N/A
- P/E Ratio
- CVKD N/A
- PWM N/A
- Revenue Growth
- CVKD N/A
- PWM N/A
- 52 Week Low
- CVKD $5.40
- PWM $0.67
- 52 Week High
- CVKD $32.55
- PWM $2.50
- Technical
- Relative Strength Index (RSI)
- CVKD 61.78
- PWM 46.65
- Support Level
- CVKD $10.65
- PWM $1.27
- Resistance Level
- CVKD $12.25
- PWM $2.25
- Average True Range (ATR)
- CVKD 1.68
- PWM 0.31
- MACD
- CVKD 0.32
- PWM -0.03
- Stochastic Oscillator
- CVKD 76.54
- PWM 13.83
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
About PWM Prestige Wealth Inc.
Prestige Wealth Inc is engaged in providing private wealth management services and asset management to high-net-worth and ultra-high-net-worth individuals and enterprises through its subsidiaries.